Invex Therapeutics Ltd.
AASX:IXC0.11
AUD
0.00
(0.00%)
Invex Therapeutics Ltd.
ASX:IXC
(Australian Securities Exchange)
Recent
price
0.11
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Invex Therapeutics Ltd (ASX:IXC) is a biopharmaceutical company focused on the research, development and repurposing of exenatide, an approved glucagon-like peptide-1 receptor agonist, trademarked as Presendin, for the treatment of neurological conditions associated with raised intracranial pressure, including idiopathic intracranial hypertension, acute stroke, traumatic brain injury, Alzheimer's disease and hydrocephalus; the company conducts clinical trials, preclinical studies and intellectual property development in these therapeutic areas. Founded in 2019 and headquartered in Perth, Australia, with prior addresses in Subiaco, Western Australia, Invex operates primarily in Australia and the United Kingdom, targeting patients and healthcare providers in the pharmaceuticals and biotechnology sectors globally. Recent developments include the closure of its Phase III EVOLVE clinical trial for idiopathic intracranial hypertension, expansion of a research collaboration agreement with Tessara Therapeutics Pty Ltd in March 2025 to evaluate exenatide's efficacy in an Alzheimer's disease model and potential new intellectual property, the collapse of exclusive acquisition negotiations on September 29, 2025, with a rare neurological disease therapeutics company due to boardroom uncertainty from a shareholder requisition to remove two directors, a deferral of its annual general meeting to November 20, 2025, and a change of registered office and principal place of business to Level 3, 101 St Georges Terrace, Perth WA 6000 effective November 10, 2025; the company continues to pursue complementary neurological assets and divestiture of core IP related to GLP-1 receptor agonists for raised intracranial pressure disorders.